Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
With
XOMA (US) LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Clinical diagnosis of CLL requiring treatment
Refractory or relapsed disease
Prior treatment with fludarabine
Male or Female
\>18 years of age
You may not be if
Treatment with rituximab within 90 days and alemtuzumab or any monoclonal antibody within 6 months.
Clinically significant cardiac dysfunction or other significant organ dysfunction
Additional eligibility criteria apply that will be reviewed with potential study subjects at the site.
Clareo Health | Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy
